Stroke
June 2016 The distribution of CHADS 2 scores and their respective ages for the baseline model population was derived from a nationally representative sample of commercially insured patients with AF who were eligible to receive anticoagulant therapy. 33 The model structure was adapted from the studies published by Lee et al [14] [15] [16] ( Figure 1 ). All the patients entered the model in the Well with atrial fibrillation state on an OAC and then transitioned to the other health states. We assumed that 28% of all the ischemic strokes were transient ischemic attacks, and the remaining could be 1 of 4 types: reversible, major, minor, or fatal. Intracranial hemorrhage (ICH) could be of 3 types: major, minor, and fatal. After a patient experienced an ICH or extracranial hemorrhage (ECH), anticoagulation was assumed to be discontinued and the patient switched to aspirin for the remainder of their lifetime. Consistent with Lee et al, we assumed that after 2 minor neurological events, patients would proceed to a major event health state and 2 major events would lead to death. [14] [15] [16] To estimate net monetary benefits, we used a willingness to pay (WTP) threshold of $100 000 per qualityadjusted life year (QALY) based on the World Health Organization cost-effectiveness guidances. 34 Costs and utilities were discounted at a rate of 3% (range, 0%-5%).
Model Input Parameters
Key model input parameters are provided in Table 1 , and a complete list of all input parameters, their distributions, and sources are provided Table I in the online-only Data Supplement.
Costs
All the costs were considered from a payer's perspective, and we included only direct medical costs. The event costs of ICH, myocardial infarction (MI), stroke, and ECH and the follow-up costs of stroke, MI, and ICH were derived from AF-specific event and followup cost estimates. 35 All event and follow-up costs were inflated using the medical component of the consumer price index to USD 2015. 36 An alternate costing strategy was also used in which all the event and follow-up costs from the article of Lee et al 15 were inflated to 2015 dollars.
Drug costs were estimated using the National Average Drug Acquisition cost as of April 2015 compiled by the US Medicaid program. 37 To more accurately reflect a payers' perspective in which negotiated rebates are common when there are multiple branded products in a therapeutic category, we applied an average rebate of 23% to our National Average Drug Acquisition drug cost estimates. 38 The variance estimates for drug costs were derived from the pharmacy claims of a commercial insurance database.
Health-Related Quality of Life and Utilities
We awarded utilities to each simulated patient to estimate QALY. Major or minor neurological events (major or minor, stroke, or ICH) were associated with a permanent disutility. ECH, MI, and minor bleed were assigned temporary disutilities. MI, ECH, and minor bleed were assigned a disutility of 30 days, 2 weeks, and 2 days, respectively.
Probabilities
The stroke rates for patients on warfarin at each CHADS 2 score were derived from the Anticoagulation and Risk Factors in Atrial Fibrillation cohort. 39 Relative risks for an increase in ICH and stroke risk with every decade were based on systematic reviews and pooled analysis from clinical trials.
40, 41 The hazard ratios (HRs) with respect to warfarin for each of the events for the NOACs were derived from their respective clinical trials. [8] [9] [10] [11] The relative risk for each of the outcomes for aspirin in comparison with warfarin was based on a network meta-analysis.
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Analysis
Model development, implementation, and analysis were performed using TreeAge Pro 2015. Technical verification of the model was performed by 2 of the authors (Anuj Shah and Anand Shewale) independently constructing the initial model in TreeAge and replicating findings. For the base case analysis, we simulated a hypothetical cohort of 10 000 patients. A gamma distribution was used for all the costs, log-normal distribution for relative risk and HR, β distribution for utilities and probabilities, and a normal distribution for age.
Sensitivity Analyses
We performed a 1-way sensitivity analysis on the influential model input parameters that were identified by visual inspection of tornado diagrams (Figures I-VIII in the online-only Data Supplement). We performed 2 probabilistic sensitivity analyses by generating 100 cohorts of 10 000 patients, 1 with the trial-based variances (base case) for NOAC efficacy and 1 with variance estimates inflated by 50% to account for potential patient heterogeneity of the NOACs pivotal trials. We also conducted a structural sensitivity analysis by making the assumption that all patients who developed an MI after an ECH or ECH after MI would stay on aspirin but acquire the monthly follow-up cost of MI patients. We performed a sensitivity analysis by altering the costing strategy and inflating the costs used by Lee et al. 15 To test the sensitivity of our model to cost estimates of NOACs, we assigned National Average Drug Acquisition cost (without rebate) and Medispan Average Wholesale Price as the mean cost estimates in 2 separate scenarios. In addition, we performed subgroup analyses among patients aged <65 and ≥65 years and among patients with CHADS 2 scores of 1, 2, and ≥3.
Results
Base Case
In the base case analysis, apixaban had the highest QALY (9.38; 95% CI, 9.24-9.48 QALYs) followed by dabigatran and was lowest for warfarin (9.02; 95% CI, 8.90-9.12 QALYs; Table 2 ). The costs were the lowest for warfarin ($46 241; 95% CI, $44 499-$47 874) and highest for rivaroxaban ($58 889; 95% CI, $57 467-$60 444). After eliminating edoxaban, rivaroxaban, and dabigatran (dominated strategies), the incremental cost-effectiveness ratio (ICER) for apixaban relative to warfarin was $25 816/QALY. All the NOACs had an ICER <$100 000/QALY relative to the common comparator warfarin.
Sensitivity Analysis
The 1-way sensitivity analysis showed dabigatran had the highest net monetary benefit using a threshold of 100 000/ QALY under the following conditions: (1) when the HRs of ICH, MI, and stroke for apixaban were above 0.46, 1.05, and 0.99, respectively; (2) when the HRs of ICH, MI, ECH, and stroke for dabigatran were below 0.36, 1.17, 0.82, and 0.70, respectively; (3) when the annual stroke rate on warfarin was >0.02. Edoxaban had the highest net monetary benefit when the HRs of ICH and stroke for edoxaban were below 0.38 and 0.89. To become the preferred strategies at a WTP threshold of $100 000/QALY, monthly drug costs would have to be reduced by $63 and $30 for edoxaban and dabigatran, respectively. The probabilistic sensitivity analyses for the base case scenario and the scenario with the SDs of the efficacy estimates showed that apixaban was cost-effective in 98% and 61% of the iterations, respectively, at a WTP of $100 000/ QALY( Figure 2) .
The structural sensitivity analysis resulted in edoxaban being extendedly dominated and dabigatran and rivaroxaban absolutely dominated. Apixaban had an ICER of $24 566 per QALY (Table 3) relative to warfarin. The alternate costing strategy based on Lee et al showed apixaban and dabigatran having an ICER <$100,000 per QALY and edoxaban and rivaroxaban were absolutely dominated (Table 3) . When National Average Drug Acquisition cost and Average Wholesale Price based cost were used, apixaban dominated all other NOACs with an ICER <100 000 per QALY (Table 3) .
Subgroup Analyses
In the 2 cohorts of patients with incident AF above and below 65 years of age, all of the NOACs were absolutely or extendedly dominated by apixaban (Table 3) . For those with a CHADS 2 score of 1 or 2, apixaban was found to be cost-effective at a WTP threshold of $50 000 per QALY dominating the other NOAC strategies (Table 3) . For patients with a CHADS 2 score of ≥3, dabigatran dominated the other NOACs (Table 3) .
Discussion
The objective of this study was to compare and contrast the cost-effectiveness of all the OACs available for stroke prophylaxis among patients diagnosed with atrial fibrillation in the United States. Our reference therapy was adjusted dose warfarin that has been identified as the standard therapy in AF management guidelines. Our model shows that all the NOACs are more effective than warfarin; however, the QALY difference between apixaban (most effective NOAC) and rivaroxaban (least effective NOAC) is a modest 50 days. In our base case scenario and across most of our sensitivity analyses, apixaban was determined to be the most cost-effective strategy dominating all other strategies except warfarin. This finding was relatively robust in our base case probabilistic sensitivity analyses; however, the probabilistic sensitivity analyses that used inflated variance estimates from the pivotal trials showed considerably more uncertainty.
There are a few scenarios in which apixaban would not be the preferred anticoagulant, however. When the effectiveness of dabigatran increased or the effectiveness of apixaban decreased or the baseline rate of stroke increased, dabigatran became the most cost-effective. Similarly, the cost-effectiveness of apixaban was also sensitive to the effectiveness estimates of edoxaban. Given the relatively modest QALY differences between NOACs and, in particular, between dabigatran, apixaban, and edoxaban, the preferred NOAC may change as more clinical data become available for the NOACs.
The prices of dabigatran and edoxaban also had a meaningful impact on the cost-effectiveness results. If the monthly costs of dabigatran and edoxaban was lowered by ≈13% and 30%, respectively, the ICER for apixaban exceeds $100 000/ Cost-effectiveness (CE) acceptability curve (probability that a treatment will be cost-effective at varying willingness-to-pay thresholds). The percentage of iterations that showed the particular therapy to be CE are plotted on the y-axis vs varying willingness to pay thresholds (plotted in terms of dollars a payer is willing to pay to achieve an additional quality-adjusted life-year for a patient) on the x-axis. A, Depicts the CE acceptability curve for the base case scenario. B, The CE acceptability curve after inflating the standard deviations of the efficacy measures for the newer oral anticoagulants by 50%.
QALY. This finding is particularly relevant for those managing formularies in which rebates and discounts are often negotiated. This is the first study from a US payer perspective to compare all 5 OACs available in the market. There is only 1 study from the UK perspective that compares all 5 OACs simultaneously and our findings are similar to their findings, where they also found apixaban to be the preferred therapy. 43 Our base case estimates show that apixaban and edoxaban are costeffective at a WTP of $50 000/QALY, but all NOACs are considered rational choices at a WTP of $100 000/QALY when compared individually with warfarin. This is in contrast with other models from the US perspective that determined NOACs to be cost-effective at a WTP of $50 000/QALY. [14] [15] [16] 18, 19, [21] [22] [23] 31 This could possibly be because the fact that all the other models look only at patients who are aged ≥65 years, who would have higher stroke risk.
Our model improves on the previous models by mirroring the AF population in the United States. Other models assumed all patients start at a common age and CHADS 2 score, 12,14-16,18,19,21-24,31 and we believe that our findings better represent the broad AF population that would be candidates for anticoagulation than previous studies. Another difference between our work and previous modeling studies is our costing approach. The majority of previous studies have used HCUPnet and the study of Holloway et al 44, 45 to derive event costs of the cerebrovascular accidents (CVAs), MI, and ECH, and used the study of Leibson et al 44 to derive the follow-up costs for the CVAs. These studies only consider national averages and are not specific to the AF population; in addition, the studies by Leibson et al 44 and Holloway et al 45 were conducted in 1996, and the estimates based on these data are ≈20 years old and may not be reflective of current clinical care of a CVA. We used the estimates by Forrester et al 35 to derive our cost estimates that report the incremental costs of CVAs among an AF population. The results of this model should be interpreted while considering the following limitations. First, the effectiveness estimates (probabilities and HRs) used in this model are based on clinical trials without head-to-head comparisons with durations much shorter than the lifetime horizon we modeled. To partially account for the indirect evidence from the pivotal clinical trials, we ran a simulation with inflated variance estimates. Like previous modeling studies, we did not directly model changes in adherence for NOACs or time in therapeutic range for warfarin that may overestimate the QALY of all anticoagulants. The model also does not account for incident diabetes mellitus, congestive heart failure, and hypertension, which increases the CHADS 2 score over time and in turn increases stroke risk. This may overstate QALY of all the anticoagulants, however, may differentially underestimate survival gains of anticoagulants that confer the greatest stroke risk reduction such as dabigatran. Finally, we did not make temporary states to model transitory increased risk of recurrent events immediately after an event.
Conclusions
All the NOACs we compared were more effective than adjusted dosed warfarin; however, the QALY among all NOACs was similar. Our model showed that apixaban had the highest QALY in a general AF population and has an ICER <$50 000/ QALY. For those with higher stroke risk (CHADS 2 ≥3), dabigatran had the highest QALY and an ICER <$50 000/QALY. Given the similarity of the QALY of most NOACs, the costeffectiveness of several strategies was sensitive to drug prices and efficacy estimates.
Disclosures
None. Abs dom indicates absolutely dominated; AWP, average wholesale price; CHADS 2 , congestive heart failure (1 point), hypertension (1 point), age ≥75 years (1 point), diabetes mellitus (1 point), stroke (2 points); Ext dom, extendedly dominated; MI, myocardial infarction; and NADAC, National Average Drug Acquisition Cost.
*For all scenarios in this table, except CHADS 2 ≥3 and cost sensitivity analyses 1 therapies are in presented in increasing order of cost. For complete cost, quality-adjusted survival and net monetary benefit information on all the scenarios please refer to the Table II in the online-only Data Supplement.
†Deriving event costs by inflating costs of Lee et al. 15 ‡Using the Medispan AWP as mean drug cost estimates. §Using the NADAC as mean drug cost estimates. ║Assigning MI follow-up costs to patients who get an MI in the post-extracranial hemorrhage phase as well. 
